ESC 365 - Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis

Back

ESC Premium Access

Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis

Session: Pulmonary arterial hypertension: risk stratification guides for new treatments and informed outcomes

Topic: Pulmonary Hypertension

Speaker: Doctor J. Coghlan (London, GB)

Event: ESC Congress 2021 - The Digital Experience

Presentation

About the speaker

Doctor John G Coghlan

Royal Free Hospital, London (United Kingdom of Great Britain & Northern Ireland)

4 presentations

0 follower

4 more presentations in this session

Non-invasive risk prediction based on right ventricular function in patients with pulmonary arterial hypertension

Speaker: Mrs V. Qaderi (Hamburg, DE)

Inclusion of echocardiographic measure of right ventricular function in the non-invasive French pulmonary arterial hypertension risk stratification method

Speaker: Doctor C. Fauvel (Rouen, FR)

Twenty-year experience and outcomes in a national paediatric pulmonary hypertension service

Speaker: Doctor A. Constantine (London, GB)

Safety, tolerability, and pharmacokinetics (PK) of treprostinil palmitil inhalation powder (TPIP): a phase 1, randomised, double-blind, single- and multiple-dose study

Speaker: Doctor F. Ismat (Bridgewater, US)

Access the full session

Pulmonary arterial hypertension: risk stratification guides for new treatments and informed outcomes

Speakers: Doctor J. Coghlan, Mrs V. Qaderi, Doctor C. Fauvel, Doctor A. Constantine, Doctor F. Ismat

Access

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

Heart failure as a complication of covid-19 infection: systematic review and meta-analysis

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis

About the speaker

Doctor John G Coghlan

4 more presentations in this session

Non-invasive risk prediction based on right ventricular function in patients with pulmonary arterial hypertension

Inclusion of echocardiographic measure of right ventricular function in the non-invasive French pulmonary arterial hypertension risk stratification method

Twenty-year experience and outcomes in a national paediatric pulmonary hypertension service

Safety, tolerability, and pharmacokinetics (PK) of treprostinil palmitil inhalation powder (TPIP): a phase 1, randomised, double-blind, single- and multiple-dose study

Access the full session

Pulmonary arterial hypertension: risk stratification guides for new treatments and informed outcomes

About the event

ESC Congress 2021 - The Digital Experience

Related content

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

Heart failure as a complication of covid-19 infection: systematic review and meta-analysis

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

This platform is supported by